My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 524082 | NSE: | Pharmaceuticals & Drugs | Small Cap
1. Is a good quality company?
Data is not available for this company.
2. Is undervalued or overvalued?
No data found
3. Is a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'01 | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | TTM | |||
| ROCE % ⓘ | 7.5% | 14% | -15.1% | 30.8% | 14% | 23.9% | 19.8% | 11.5% | 12.9% | 16.5% | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 2.7 | 1.4 | 0.4 | 0.8 | 0.7 | 0.8 | 1 | 0.9 | 4.5 | 5.7 | 6 | ||
| YoY Gr. Rt. % | - | -49.5% | -74.6% | 114.3% | -4% | 15.3% | 20.5% | -13% | 417.2% | 26.2% | - | ||
| Adj EPS ⓘ | 0.5 | 1 | -1.7 | 4.6 | 2.9 | 6 | 5.5 | 3.2 | 3.6 | 5.6 | 6.5 | ||
| YoY Gr. Rt. % | - | 96.2% | -258.7% | NA | -36.6% | 104.8% | -8.6% | -41.1% | 12.5% | 54.3% | - | ||
| BVPS (₹) ⓘ | 7.1 | 7.2 | 5.7 | 10.3 | 13.3 | 19.2 | 24.7 | 27.9 | 31.6 | 36 | 42.4 | ||
| Adj Net Profit ⓘ | 0.1 | 0.1 | -0.2 | 0.4 | 0.3 | 0.6 | 0.5 | 0.3 | 0.3 | 0.5 | 1 | ||
| Cash Flow from Ops. ⓘ | -0.1 | 0.2 | 1 | 0 | 0.9 | 1.1 | 0.9 | 1.1 | 0.8 | 0.2 | - | ||
| Debt/CF from Ops. ⓘ | -0.3 | 0.2 | 0.5 | -163.7 | 1.7 | 0.7 | 0.8 | 0.4 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 8.5% | 51.2% | 78.4% | 26.2% | ||||||||
| Adj EPS ⓘ | 29.9% | 13.9% | 0.7% | 54.3% | ||||||||
| BVPS ⓘ | 19.8 | 22.1 | 13.4 | 14 | ||||||||
| Share Price | - | - | - | - | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'01 | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | TTM | ||
| Return on Equity % ⓘ | 7.8 | 14.6 | -25.5 | 57.1 | 24.7 | 36.7 | 24.8 | 12.2 | 12.1 | 16.5 | 16.5 | |
| Op. Profit Mgn % ⓘ | 5.2 | 15.5 | -240.3 | -187.9 | -195.5 | -200.2 | -174.6 | -212.4 | 21.9 | 20.4 | 21.5 | |
| Net Profit Mgn % ⓘ | 1.9 | 7.2 | -44.3 | 58 | 38.6 | 68.3 | 52 | 35 | 7.6 | 9.3 | 9.9 | |
| Debt to Equity ⓘ | 0 | 0 | 0.9 | 1.5 | 1.2 | 0.4 | 0.3 | 0.2 | 0 | 0 | - | |
| Working Cap Days ⓘ | 61 | 81 | 255 | 125 | 167 | 110 | 171 | 270 | 85 | 101 | 0 | |
| Cash Conv. Cycle ⓘ | -15 | 32 | 44 | -37 | 29 | 2 | 27 | 74 | -22 | -7 | 0 | |
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Net Profit has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 6.5 | - |
| TTM Sales (₹ Cr.) | 6.2 | - |
| BVPS (₹.) ⓘ | 42.4 | - |
| Reserves (₹ Cr.) ⓘ | 3 | - |
| P/BV ⓘ | 0.64 | - |
| PE ⓘ | 4.17 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 27.00 / 27.00 |
| All Time Low / High (₹) | 9.98 / 39.95 |
| Market Cap (₹ Cr.) | 2.6 |
| Equity (₹ Cr.) | 1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 38.5 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Harleystreet Pharmaceuticals Limited was incorporated in1982 and has its registered office at Plot No.142 AB, Kandivli Industrial Estate, Kandivli (West) Mumbai Maharashtra.
Business profile:
The company is engaged in the manufacture and sale of pharmaceuticals in India. It provides formulations of ondansetron. The company offers its products in various forms, including tablets, capsules, liquids, and vials/ampoules.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
